Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on November 12, 2019. The filing addresses a critical corporate governance event regarding the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary material event is the initiation of delisting proceedings by Nasdaq. On November 12, 2019, the company received a formal Delisting Notice confirming its failure to meet the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). This deficiency persisted for 30 consecutive business days. The company had previously received a Notification Letter on November 12, 2018, and was granted two 180-day compliance periods, the second of which expired on November 12, 2019.
Outlook, Risks, and Management Commentary
- Appeal Process: The company intends to appeal the delisting determination to a Nasdaq hearing panel by November 19, 2019.
- Compliance Plan: Management plans to present a strategy to regain compliance at the hearing and requests a stay of delisting proceedings pending the panel's decision.
- Risks: There is no assurance that the hearing will be granted, that the panel will rule in the company's favor, or that the company will achieve compliance within any additional timeframe granted.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from anticipated outcomes regarding the listing status.
Investor Verification Checklist
- Verify the current trading status of PHIO stock on The Nasdaq Capital Market.
- Confirm the outcome of the Nasdaq hearing panel appeal scheduled after November 19, 2019.
- Review the company's specific plan to regain the $1.00 minimum bid price.
- Monitor for subsequent filings regarding the final decision on the delisting notice.